CSF2 and neoplasm: Single genetic modifications to express cytokines like Flt3L, GM-CSF, or IP-10 usually do not show any significant anti-tumor activity by themselves unless combined with immune checkpoint blockade or preimmunization strategies with the genetically modified irradiated metabolically active tumor cells before being exposed to live tumor cells [30–32].